Bristol-Myers Squibb Co. (NYSE:BMY)

investor research

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, Apple, FireEye, JDSU Uniphase, Solar Stocks and More

Stocks were firm on Tuesday morning during a shortened week that actually will be full of economic reports. 24/7 Wall St. reviews dozens of analyst research reports each morning of ...
Read Full Story »
Pills

Upcoming Binary Events Could Lift These Health Care Stocks Much Higher

Binary events in the health care arena can be huge in determining just how well investors do and their stocks perform. Medical meetings, clinical data and of, course, decisions by ...
Read Full Story »
Monkey evil

Top Analyst Upgrades and Downgrades: Apple, Lululemon, Microsoft, NBG, Twitter, Whole Foods and More

Stocks are looking for direction after the European Central Bank decision. Investors are being conditioned almost daily by the financial media that the bull market has now turned into a ...
Read Full Story »
down market

Why You Buy Big Pharma If the Market Crashes

Defensive sectors have done well this year, with utilities leading the way. One of the reasons is that despite the market hitting new all-time highs, there remains a wall of ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Cisco, Kinder Morgan, Rackspace, Twitter and More

Stocks pulled back off their all-time highs, and now investors have to be nimble to find gains while not catching the top of a market. These same investors are getting ...
Read Full Story »
DNA

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Since March 4, the biotech index is off a massive 19%. There has been plenty of Wall Street speculation on why the sell-off was so violent, but at the end ...
Read Full Story »
Pfizer logo

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

With the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone rangers when it came to ...
Read Full Story »
Pills

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

Wall Street firms are famous for their ability to throw conference after conference, year after year. Some are highly respected, and a must-attend for investment firms and portfolio managers. Others ...
Read Full Story »
DNA

Mallinckrodt May Have to Pay More for Cadence

Cadence Pharmaceuticals Inc. (NASDAQ: CADX) agreed Tuesday to be bought out by Mallinckrodt PLC (NYSE: MNK) for $1.3 billion, or $14 a share, in cash. There appears to be some speculation ...
Read Full Story »
NYSE-flag

The Best of the Best Picks of the Credit Suisse Top 50 Stocks

Most of the firms that we cover on Wall Street have presented their high conviction stock picks for 2014. The analysts at Credit Suisse have taken a little bit longer ...
Read Full Story »
Pills

Shire, Novartis Deals: Pharmaceutical Shakeups Continue

The wave of mergers and acquisitions in health care continues with two big announcements Monday. Drug maker Shire PLC (NASDAQ: SHPG) will acquire the rare disease biopharmaceutical company ViroPharma (NASDAQ: ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: ARM, Crocs, GE, NOV and More

Earnings season is in full swing and equities are challenging new highs almost daily. Traders and investors are looking for stocks to buy and for ideas on which stocks to ...
Read Full Story »
Pills

Credit Suisse Major Drug Stocks to Buy for Great Gains Ahead

The drug and pharmaceutical sector is supposed to be a defensive one by nature, even if this week's government shutdown and impending debt ceiling weighed heavily on biotech stocks. Credit ...
Read Full Story »
Pills

Jefferies Raises Price Targets on Pharmaceutical Stocks to Buy

As the pharmaceuticals industry looks toward restructuring and separation of undervalued assets, Jefferies analysts have prepared a highly proprietary sum of the parts analysis for their coverage universe to find ...
Read Full Story »
Bull and Bear figures

Closing Bell for Wednesday on Wall Street: Markets Blunted on Fed Comments, Minutes

U.S. equity markets opened barely higher this morning following a report that mortgage loan applications had fallen by 9.8% from the previous week, on top of a 7% decline for ...
Read Full Story »